A Phase 3, Randomized, Placebo Controlled, Prospective, Multicenter Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

Trial Profile

A Phase 3, Randomized, Placebo Controlled, Prospective, Multicenter Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Ferric maltol (Primary)
  • Indications Iron deficiency anaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms AEGIS CKD; AEGIS-3
  • Sponsors Iron Therapeutics; Shield Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 20 Sep 2016 According to a Shield Therapeutics media release, first patient is expected to enrol during Q4-2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top